Proxymetacaine
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Topical (eye drops) |
| ATC code | S01HA04 (WHO) |
| Pharmacokinetic data | |
| Metabolism | Plasma |
| Identifiers | |
| |
| CAS Number |
499-67-2  5875-06-9 (HCl) |
| PubChem (CID) | 4935 |
| IUPHAR/BPS | 7283 |
| DrugBank |
DB00807 |
| ChemSpider |
4766 |
| UNII |
B4OB0JHI1X |
| KEGG |
D08448 |
| ChEMBL |
CHEMBL1196 |
| ECHA InfoCard | 100.007.169 |
| Chemical and physical data | |
| Formula | C16H26N2O3 |
| Molar mass | 294.389 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Proxymetacaine (INN) or proparacaine (USAN) is a topical anesthetic drug of the aminoester group.
Indications and usage
Proxymetacaine hydrochloride ophthalmic solution (eye drops) is indicated for procedures such as tonometry, gonioscopy, removal of foreign bodies, or other similar procedures requiring topical anesthesia of the cornea and conjunctiva.
Warnings
Proxymetacaine is for topical ophthalmic use only, and it is specifically not intended for injection. Prolonged use of this or any other topical ocular anesthetic may produce permanent corneal opacification with accompanying visual loss.
Mechanism of action
Proxymetacaine is believed to act as an antagonist on voltage-gated sodium channels to affect the permeability of neuronal membranes; how this inhibits pain sensations and the exact mechanism of action of proxymetacaine are, however, unknown.
How supplied
Proxymetacaine is available as its hydrochloride salt in ophthalmic solutions at a concentration of 0.5%. Although it is no longer on patent, it is still marketed under the trade names Alcaine, Ak-Taine, and others. Proparacaine 0.5% is marketed as Poencaina by Poen Laboratories.